New Four-in-One antibody takes on Hard-to-Treat cancers

NCT ID NCT04794972

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called GNC-039 in people with advanced solid tumors, including a type of brain cancer called glioma, that have come back or spread. The main goals are to check the drug's safety, find the best dose, and see if it can help control the disease. About 60 adults will take part in this study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain glioma glioma malignant glioma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOMA SOLID TUMOR

Contacts and locations

Locations

Affiliated Cancer Hospital of Chongqing Medical University
RECRUITING

Chongqing, Chongqing Municipality, China
Beijing Tiantan Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100070, China
Shenzhen Second People's Hospital
RECRUITING

Shenzhen, Guangdong, China
The First Affiliated Hospital of Xi'an Jiao Tong University
RECRUITING

Xian, Shanxi, China
West China Hospital，Sichuan University
RECRUITING

Chengdu, Sichuan, China
ZhuJiang Hospital of Southern Medical University
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.